2018 International Congress

Saturday, October 6, 2018

1:45pm-3:15pm

Remotely supervised home-based aerobic exercise for Parkinson patients

N. vd Kolk, N. de Vries, B. Post, B. Bloem (Nijmegen, Netherlands)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Resting-state fMRI study on drug-naive essential tremor patients with head tremor

L. Wang, N. Li, X. Suo, Z. Lu, J. Li, J. Peng, Q. Gong, R. Peng (Chengdu, Sichuan Province, China)

Neuroimaging (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

Reversible asymmetric parkinsonism and vertical gaze limitation as an initial manifestation of dural arteriovenous fistula

W. Yoon (Seoul, Republic of Korea)

Neuroimaging (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

Review of mealtime difficulties following frontotemporal lobar degeneration

C. Lewis, A. Vogel, M. Walterfang, D. Velakoulis (Melbourne, Australia)

Cognitive Disorders  ·  Hall 3FG

1:45pm-3:15pm

Role of metformin in diabetic aging female rat brain: a future therapy for neurodegenerative diseases

P. Kumar, N. Baquer (New Delhi, India)

Neuropharmacology  ·  Hall 3FG

1:45pm-3:15pm

Rose Anthocyanins protect against Parkinson’s pathophysiology: Behavioral and biochemical changes in young Drosophila

G. Chandran, P. Chandrashekar, M. Jayaraju, J. Chauhan (Mysuru, India)

Pediatric Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes

M. Asanuma, I. Miyazaki, N. Isooka, R. Kikuoka, K. Wada, E. Nakayama, K. Shin, D. Yamamoto, Y. Kitamura (Okayama, Japan)

Neuropharmacology  ·  Hall 3FG

1:45pm-3:15pm

Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson’s Disease

J. Boyd, C. Zadikoff, M. Siddiqui, J. Benesh, J. Zamudio, W. Robieson, P. Kukreja (Burlington, VT, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial

R. Pahwa, R. Hauser, M. Worden, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Kansas City, KS, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG